Menu

Medical

Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA® (pembrolizumab) for the Treatment of Multiple Types of Cancer

, , , ,

Collaboration Combines Merck’s Leadership in Immuno-Oncology with Moderna’s Pioneering mRNA Vaccine Technology and Rapid Cycle Time, Small-Batch GMP Manufacturing Capabilities KENILWORTH, N.J. & CAMBRIDGE, Mass. June 29, 2016 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Moderna Therapeutics today announced a strategic collaboration and license agreement to develop and commercialize […]

Two Additional Phase 3 Lipid-Lowering Studies of Bococizumab Deliver Positive Topline Results

, , , ,

SPIRE-HR and SPIRE-FH trials met primary endpoints in patients at high and very high risk for cardiovascular events June 28, 2016 – Pfizer Inc. announced two additional Phase 3 bococizumab trials, SPIRE-HR (HighRisk) and SPIRE-FH (Familial Hypercholesterolemia), met their primary endpoint, demonstrating a significant reduction in the percent change from baseline in low-density lipoprotein cholesterol […]

Pfizer Advances Biosimilars Leadership with Investment in a New World-Class Global Biotechnology Center in China

, ,

Pfizer’s state-of-the-art facility will foster the continued development of the biotechnology industry in China, further supporting National healthcare reforms June 27, 2016 – Pfizer Inc. today announced that it will invest approximately USD$350 million in the development of a state-of-the-art Global Biotechnology Center at a ground-breaking ceremony in the Hangzhou Economic Development Area (HEDA) in […]

MDLIVE Expands Behavioral Health Services with Free Online Assessments and Advice for Common Behavioral Issues

,

Company launches new tools to evaluate stress, relationship problems, and more. Sunrise, Florida, June 10, 2016 — MDLIVE, the nation’s leader in the rapidly growing virtual health market, today announced the launch of several new tools designed to help individuals evaluate their behavioral health needs. The company’s teletherapy services are offered through Breakthrough, an MDLIVE […]

Larry Gleit Named General Manager for MDLIVE/Behavioral Health and Breakthrough, an MDLIVE Company

,

SUNRISE, Florida, May 20, 2016 — MDLIVE, the nation’s leader in the rapidly growing virtual health market, today announced that Larry Gleit has been named general manager for MDLIVE/Behavioral Health and Breakthrough, an MDLIVE company, effective immediately. “Larry Gleit has the experience and expertise to lead our teletherapy business forward as we expand our capabilities […]

Tom Barone Named President and Chief Operating Officer of MDLIVE

,

SUNRISE, Fla., May 20, 2016 — MDLIVE, the nation’s leader in the rapidly growing virtual health market, today announced that Tom Barone has been appointed president and chief operating officer. Barone brings more than 20 years of operations, supply chain, client service, business development, call center, eCommerce and executive leadership experience to MDLIVE from companies […]

Edwards SAPIEN 3 TAVR Demonstrates Clinical Superiority To Surgery In PARTNER II Study

, , , ,

Trial Studied Severe, Symptomatic Aortic Stenosis Patients at Intermediate Risk for Surgery CHICAGO, April 3, 2016 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that new data on patients at intermediate risk for open-heart surgery demonstrated that transcatheter aortic valve replacement […]

Edwards SAPIEN XT Valve Meets Primary Endpoint In PARTNER II Trial

, , , ,

CHICAGO, April 2, 2016 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the randomized PARTNER II Trial comparing the SAPIEN XT valve to surgery in intermediate-risk patients successfully achieved its primary endpoint at two years. The results of the study […]

Phase 3 Study Findings Demonstrate Treatment with Baricitinib Results in Significant Improvements for Patients with Rheumatoid Arthritis Who Had Inadequate Response to Biologics

, , ,

Pivotal RA-BEACON Study Published in New England Journal of Medicine INDIANAPOLIS, March 31, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced that detailed results of RA-BEACON — a pivotal phase 3 global study of baricitinib, a once-daily oral treatment currently under regulatory review for the treatment of moderate-to-severe […]

Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016

, , , ,

Presentations Include Results from Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) Compared to Sofosbuvir-Containing Regimen, and Results from Studies in Difficult-to-Treat Populations March 30, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the planned presentations of data from the company’s broad chronic hepatitis C […]

«‹ 18 19 20 21›»